Literature DB >> 28346966

Factor XII Contact Activation.

Clément Naudin1,2, Elena Burillo1,2, Stefan Blankenberg3, Lynn Butler1,2, Thomas Renné1,2.   

Abstract

Contact activation is the surface-induced conversion of factor XII (FXII) zymogen to the serine protease FXIIa. Blood-circulating FXII binds to negatively charged surfaces and this contact to surfaces triggers a conformational change in the zymogen inducing autoactivation. Several surfaces that have the capacity for initiating FXII contact activation have been identified, including misfolded protein aggregates, collagen, nucleic acids, and platelet and microbial polyphosphate. Activated FXII initiates the proinflammatory kallikrein-kinin system and the intrinsic coagulation pathway, leading to formation of bradykinin and thrombin, respectively. FXII contact activation is well characterized in vitro and provides the mechanistic basis for the diagnostic clotting assay, activated partial thromboplastin time. However, only in the past decade has the critical role of FXII contact activation in pathological thrombosis been appreciated. While defective FXII contact activation provides thromboprotection, excess activation underlies the swelling disorder hereditary angioedema type III. This review provides an overview of the molecular basis of FXII contact activation and FXII contact activation-associated disease states. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28346966     DOI: 10.1055/s-0036-1598003

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  30 in total

1.  Elevated extracellular trap formation and contact system activation in acute leukemia.

Authors:  Tae Yeul Kim; Ja-Yoon Gu; Hye Soo Jung; Youngil Koh; Inho Kim; Hyun Kyung Kim
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

2.  Factor XI and pulmonary infections.

Authors:  D Gailani; B M Mohammed; Q Cheng
Journal:  Haemophilia       Date:  2018-05-29       Impact factor: 4.287

Review 3.  Single-chain factor XII: a new form of activated factor XII.

Authors:  Ivan Ivanov; Anton Matafonov; David Gailani
Journal:  Curr Opin Hematol       Date:  2017-09       Impact factor: 3.284

4.  Modeling and dynamical analysis of the full-length structure of factor XII with zinc.

Authors:  Evren Kılınç; Ahmet Can Timucin; Suleyman Selim Cinaroglu; Emel Timucin
Journal:  J Mol Model       Date:  2022-04-25       Impact factor: 1.810

5.  Contact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors.

Authors:  Sooyong Park; Ja-Yoon Gu; Hyun Kyung Kim
Journal:  J Thromb Thrombolysis       Date:  2022-01-07       Impact factor: 2.300

6.  Surface dependent contact activation of factor XII and blood plasma coagulation induced by mixed thiol surfaces.

Authors:  James W Bauer; Li-Chong Xu; Erwin A Vogler; Christopher A Siedlecki
Journal:  Biointerphases       Date:  2017-05-17       Impact factor: 2.456

Review 7.  Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces.

Authors:  Benjamin Tillman; David Gailani
Journal:  Semin Thromb Hemost       Date:  2017-09-12       Impact factor: 4.180

Review 8.  An update on factor XI structure and function.

Authors:  Bassem M Mohammed; Anton Matafonov; Ivan Ivanov; Mao-Fu Sun; Qiufang Cheng; S Kent Dickeson; Chan Li; David Sun; Ingrid M Verhamme; Jonas Emsley; David Gailani
Journal:  Thromb Res       Date:  2017-10-10       Impact factor: 3.944

9.  Combination strategies for antithrombotic biomaterials: an emerging trend towards hemocompatibility.

Authors:  Morgan Ashcraft; Megan Douglass; YuJie Chen; Hitesh Handa
Journal:  Biomater Sci       Date:  2021-02-18       Impact factor: 6.843

Review 10.  Proteolytic activity of contact factor zymogens.

Authors:  Aleksandr Shamanaev; Jonas Emsley; David Gailani
Journal:  J Thromb Haemost       Date:  2020-12-07       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.